Monday, August 10, brought another wave of Buy-equivalent upgrades. Wells Fargo lifted Dick's Sporting Goods to Overweight ahead of the August 25 earnings release, Morgan Stanley reversed to Overweight on Hewlett Packard Enterprise, Argus turned bullish on SanDisk citing a memory-cycle bottom, Goldman Sachs upgraded Protagonist Therapeutics to Buy on its oral IL-17 antagonist PN-881, and Loop Capital moved FirstCash to Buy on an oversold post-earnings setup. The July 29 FOMC held rates at 3.50%-3.75%, and CME Group's FedWatch assigns roughly 80% probability to no cuts through 2026. The five picks span retail, enterprise hardware, memory, biotech, and specialty finance.
Dick's Sporting Goods (DKS) — Wells Fargo turns bullish on the multi-year setup
Dick's Sporting Goods is the largest U.S. sporting goods retailer, expanded through the recent Foot Locker acquisition. On August 10, Wells Fargo analyst Ike Boruchow upgraded from Equal-Weight to Overweight with a $240 target (up from $220), based on 14-15x 2027 earnings and modeling fiscal 2028 EPS power above $20. Boruchow flagged three levers: margin upside at Foot Locker from better allocation and merchandising, execution at the core DSG banner, and DKS as the best way to play Nike's eventual product turnaround. Q2 reports August 25; Wells Fargo models EPS of $3.72 below Street, but sees the back-to-school and second-half outlook as more critical than the quarter itself.
Shares traded at $212.18 on August 10, up 1.60%, with a market cap of $18.1 billion, a trailing P/E of 20.17, and a small trailing dividend yield. The 52-week range is $186.67 to $244.38. The consensus rating is Strong Buy, with 11 of 13 covering analysts bullish, an average target of $263.08, a median of $270, a high of $300, and a low of $224.
Risks: Foot Locker integration remains early and consumer trade-down could pressure the back-to-school season; Nike's turnaround timing is uncertain; and Wells Fargo itself expects a weak Q2 print. Wells Fargo's own model implies below-Street EPS, and the coverage low of $224 signals limited downside cushion if execution slips.
Hewlett Packard Enterprise (HPE) — Morgan Stanley reverses course on enterprise hardware
Hewlett Packard Enterprise sells servers, storage, networking, and hybrid-cloud infrastructure, with expanded reach following the Juniper Networks acquisition. On August 10, Morgan Stanley upgraded from Equal-Weight to Overweight with a $69 target, implying roughly 30% upside from the August 7 close of $53.22. The firm called HPE its preferred OEM to play the enterprise infrastructure cycle, citing upside across servers, storage, and networking; improving free cash flow conversion; faster deleveraging; and growing capital-return optionality. Citigroup's Asiya Merchant maintains Buy at $74, and Goldman Sachs' Michael Ng maintains Buy at $79.
Shares traded at $55.12 on August 10, up 3.58%, with a market cap of $73.0 billion, a trailing P/E of 52.50, and a small trailing dividend yield. The 52-week range is $19.84 to $64.25. The consensus rating is Buy, with 11 of 16 covering analysts bullish, an average target of $69.81, a median of $69, a high of $80, and a low of $62.
Risks: Execution remains the key risk on Juniper integration; memory and storage input pricing could compress hardware gross margins; and the stock has already rerated sharply off the 52-week low. Susquehanna's Mehdi Hosseini maintains Neutral, reflecting the mixed-view camp on hardware capex durability.
SanDisk (SNDK) — Argus upgrades on memory-cycle bottom and accelerating demand
SanDisk is a leading independent supplier of NAND flash memory and data-storage products, benefiting from AI-driven enterprise-SSD demand and tight industry supply. On August 10, Argus upgraded from Hold to Buy with a $1,600 target, citing accelerating demand momentum keeping valuations reasonable and a more favorable entry after profit-taking in memory names. Argus reiterated its five-year Buy rating. Citigroup's Asiya Merchant maintains Buy at $2,100, and Morgan Stanley's Joseph Moore recently raised his Overweight target to $1,750.
Shares traded at $1,255.55 on August 10, up 3.58%, with a market cap of $185.9 billion and a trailing P/E of 17.10. The 52-week range is $42.82 to $2,354.39. The consensus rating is Strong Buy, with 13 of 15 covering analysts bullish, an average target of $1,890, a median of $2,100, a high of $3,050, and a low of $450.
Risks: The stock is well off its 52-week high, and memory pricing remains cyclical; RBC Capital's Srini Pajjuri maintains Sector Perform at $1,300, and Wells Fargo's Aaron Rakers maintains Equal-Weight at $1,400 after trimming his target from $1,620. AI-capex normalization or a NAND oversupply reversal would compress the multiple.
Protagonist Therapeutics (PTGX) — Goldman Sachs upgrades on IL-17 pipeline potential
Protagonist Therapeutics is a clinical-stage biotech developing peptide-based therapies, with a partnership on rusfertide and an emerging autoimmune pipeline led by phase 1 oral IL-17 antagonist PN-881. On August 10, Goldman Sachs analyst Richard Law upgraded from Neutral to Buy with a $186 target (up from $110), citing PN-881's potential across multiple autoimmune indications. The same day, Wedbush's Yun Zhong raised his Outperform target to $173 from $118, and Citigroup's Geoff Meacham recently raised his Buy target to $175 from $130.
Shares traded at $147.82 on August 10, up 1.34%, with a market cap of $9.5 billion. The 52-week range is $50.58 to $151.50, placing shares near a 52-week high. The consensus rating is Strong Buy, with all 13 covering analysts bullish, an average target of $132.15, a median of $118, a high of $186, and a low of $82.
Risks: Shares have more than doubled off the 52-week low and trade above the average and median analyst target, so consensus implies downside from spot; PN-881 remains in phase 1, with binary clinical-readout risk; and third-party fair-value screens flag overvaluation. HC Wainwright's Douglas Tsao maintains Buy at $80, the coverage low.
FirstCash (FCFS) — Loop Capital calls the post-earnings selloff overdone
FirstCash operates the largest pawnshop network in the U.S. and Latin America and runs an American First Finance point-of-sale lending arm, historically defensive on consumer stress. On August 10, Loop Capital analyst Anthony Chukumba upgraded from Hold to Buy with a $255 target (up from $220), calling the post-earnings selloff overdone. TD Cowen's Moshe Orenbuch maintains Buy at $240, and Canaccord Genuity's Brian McNamara maintains Buy at $252.
Shares traded at $208.62 on August 10, up 3.00%, with a market cap of $9.0 billion, a trailing P/E of 23.80, and a small trailing dividend yield. The 52-week range is $134.67 to $235.97. The consensus rating is Buy, with 2 of 3 recent covering analysts bullish, an average target of $212.33, a median of $240, a high of $252, and a low of $145.
Risks: Coverage is thin and one analyst carries a $145 target, capping consensus below spot; consumer credit stress in Latin America could pressure the AFF segment; and Mexico FX remains a recurring headwind. Loop Capital itself downgraded to Hold at $145 in September 2025 before flipping back to Buy on August 10, illustrating whipsaw risk.
Found this helpful? Share it with others.